China Leadership Changes Signal MSD-Simcere JV Shakeup
This article was originally published in PharmAsia News
Executive Summary
With the two top execs at MSD-Simcere jumping ship, there was speculation that the JV could be in trouble, but MSD reiterates its strong commitment to China and the JV as the company hastens its pace in the country to introduce more products.
You may also be interested in...
Merck’s Big Move: Massive Cost Cuts And R&D Changes Ahead
Merck will cut 8,500 positions and reduce operating costs by $2.5 billion by 2015 to jumpstart growth in the midst of slowing sales and several late-stage pipeline setbacks. A key initiative is to recharge R&D by reinvesting in key projects and increasing business development activities.
Merck, Simcere Form JV To Expand Access To Lifestyle Drugs Across China
SHANGHAI - Merck & Co. affiliate MSD signed an agreement to form a joint venture July 21 with Simcere Pharmaceutical Group that will see both companies expand access to critical lifestyle drugs across China
CROs at risk from China's new inventor regulation?
China's State Intellectual Property Office (SIPO) is drafting a new regulation on "service innovation" to encourage companies and researchers in the country to raise their investment in, and the conduct of, innovation. However, the move may also have an impact on the soaring drug discovery industry in China as it will mean higher payments to inventors with knock-on effects on local drug discovery and CROs.